An innovative vaccine to treat Parkinson's disease

Salvador Ventura

Universitat Autònoma de Barcelona (UAB), Spain

Parkinson's disease (PD) is a rapidly growing brain disorder that severely impacts movement and quality of life. Current treatments only manage early symptoms, but do not stop the disease from progressing. This project focuses on developing a new vaccine, NEUROVAX, which targets a specific region of a protein that clumps together and damages brain cells in PD patients. By blocking this region, the vaccine aims to prevent brain cell damage and improve motor and cognitive functions.

The proposed vaccine, based in nanotechnology approaches, trains the immune system to produce antibodies that specifically target the harmful protein clumps. This innovative approach has shown promising preliminary results in animal models already. Now, the researchers want to validate the effectiveness of NEUROVAX in preclinical trials, with the hope of eventually moving to human trials. They expect a significant reduction in the harmful protein clumps, improved motor and cognitive function, and a potential long-term preventive treatment for PD.

By developing a vaccine that targets the root cause of the disease, NEUROVAX offers hope for a future where PD can be prevented, significantly improving the lives of patients and their families.

• Analía Bortolozzi, Consejo Superior de Investigaciones Científicas (CSIC)

A Next-Generation Vaccine for Parkinson’s Disease

€628.288,00